Making Allogeneic Bone Marrow Transplantation Available to Patients in Developing Countries: The Mexican Experience

摘要: Non-myeloablative allogeneic stem cell transplantation (NST) has been one of the most exciting developments in treatment hematologic malignancies last years. Since 1999, we have chosen to employ Mexico a regi- men conduct NST, introducing some changes with main goal decreasing cost procedure and turn, making it available larger number patients developing countries. Using this method done over 400 al- lografts Latin American different both malignant non-malignant diseases: Chronic myelogenous leu- kemia, acute leukemia, lymphoblastic myelodysplasia, thalassemia major, relapsed Hodg- kins disease, Blackfan-Diamond syndrome, adrenoleukodystrophy, Hunters aplastic anemia several solid tumors. In whole group, median granulocyte recovery time 0.5 x 10 9 /L was 13 days, whereas platelet 20 12 days. Around third did not need red blood transfusions also transfusions. more than 70% cases could be completed totally on an outpatient basis. The follow up ranges between 30 2000 Approximately 50% lografted individuals developed graft versus host disease (GVHD), around 30% chronic GVHD. post-allograft overall survival (SV) reached day SV is 54%, 100-day mortality being 16%. group patients, each NST 18 000 USD, figure which contrasts that informed from More 95% who were allografted America using afforded conventional or expensive transplant; accordingly, enabled doctors offer therapeutic ap- proach individuals.